Страна: Малта
Език: английски
Източник: Medicines Authority
ZAFIRLUKAST
AstraZeneca UK Limited 600, Capability Green, Luton LU1 3LU, United Kingdom
R03DC01
ZAFIRLUKAST 20 mg
TABLET
ZAFIRLUKAST 20 mg
POM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
Withdrawn
2005-09-27
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What Accolate is and what it is used for 2. What you need to know before you take Accolate 3. How to take Accolate 4. Possible side effects 5. How to store Accolate 6. Contents of the pack and other information 1. WHAT ACCOLATE IS AND WHAT IT IS USED FOR Accolate contains a medicine called zafirlukast. This belongs to a group of medicines called ‘leukotriene antagonists’. This means that it reduces the effects of ‘leukotrienes’. These are natural substances in the lung that cause asthma. • Accolate is used to control the symptoms of your asthma. • It is also used to prevent your asthma from getting worse. Do not take Accolate to treat sudden (acute) asthma attacks. Your doctor will provide you with other inhalers to treat sudden attacks. 2. BEFORE YOU TAKE ACCOLATE DO NOT TAKE ACCOLATE IF: • You are allergic (hypersensitive) to zafirlukast or any of the other ingredients of this medicine (listed in Section 6). • You have a chronic liver condition. Do not take Accolate if any of the above applies to you. If you are not sure, talk to your doctor or pharmacist before taking Accolate. WARNINGS AND PRECAUTIONS Talk to your doctor or pharmacist before taking Accolate if: • You have had problems with your liver that were caused by taking Accolate. If you are not sure if this applies to you, talk to your doctor or pharmacist before taking Accolate. If you go into hospital let the medical staff know that you are taking Accolate. CHILDRE Прочетете целия документ
MT SmPC Accolate 20 mg RSP 15 0041(based on RSP 14 0065) 08/07/15 ND Page 1 of 12 1. NAME OF THE MEDICINAL PRODUCT Accolate 20 mg film-coated tablets. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 20 mg of zafirlukast EXCIPIENT WITH KNOWN EFFECT: Each tablet contains 45 mg lactose monohydrate (see section 4.4). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablets. White, round, biconvex, film-coated tablets intagliated with 'Accolate 20' on one side and plain on the reverse. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Accolate is indicated in adults and children aged 12 years and over for the prophylaxis and chronic treatment of asthma. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Accolate is taken to prevent asthma attacks and should therefore be taken continuously. POSOLOGY:: Therapy should be initiated at 20 mg twice daily. The usual maintenance dosage is 20 mg twice daily. Increasing the dose, titrating to a maximum of 40 mg twice daily, may provide additional benefit. This dose should not be exceeded because higher doses may be associated with hepatotoxicity. As food may reduce the bioavailability of zafirlukast, Accolate should not be taken with meals. Each tablet should be swallowed whole with a drink of water. SPECIAL POPULATIONS: ELDERLY: MT SmPC Accolate 20 mg RSP 15 0041(based on RSP 14 0065) 08/07/15 ND Page 2 of 12 The clearance of zafirlukast is reduced in elderly patients (>65 years old), such that C max and AUC are approximately twice those of younger adults. However, accumulation of Accolate is not evident in elderly patients. In clinical trials, elderly patients receiving a dose of 20 mg twice daily were not associated with an increase in the overall incidence of adverse events or withdrawals because of adverse events. Therapy may be initiated at 20 mg twice daily and adjusted according to clinical response. PATIENTS WITH RENAL IMPAIRMENT: Experience is limited in patients with mild to severe renal impairment, so clear d Прочетете целия документ